Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Regeneron Pharmaceuticals (REGN) Jumped, But What Is The Market Seeing Now?

Analyst downgrade Earnings report AI-generated analysis

πŸ“ˆ Regeneron reported Q3 2026 revenue of US$5.12 billion and net income of US$1.95 billion, driven by record contributions from Dupixent, EYLEA HD, and Libtayo.

πŸš€ Shares jumped 13.42% on the day and gained 22.46% over 30 days following the earnings beat and positive buyback program updates.

πŸ’° The company maintains a resilient cash flow profile and strong balance sheet, supporting its long-term growth strategy in immunology and oncology.

πŸ”¬ Regeneron is advancing a broad late-stage pipeline across genetic medicines and obesity, with new revenue streams expected from future regulatory approvals.

βš–οΈ Analyst consensus fair value stands at US$869 per share, suggesting the current price of US$928.61 is about 7% overvalued relative to standard targets.

πŸ“‰ Simply Wall St's DCF model estimates a much higher intrinsic value of US$2,505.69, creating a significant valuation gap with analyst consensus.

⚠️ Key risks include rising competition for EYLEA HD in the retinal market and potential legal challenges affecting Libtayo earnings power.

Bullish Signals
  • Regeneron delivered a strong Q3 2026 earnings beat with revenue of US$5.12 billion and net income of US$1.95 billion.
  • Record contributions from key franchises Dupixent, EYLEA HD, and Libtayo drove the company's financial performance.
  • The stock surged 13.42% on the day and 22.46% over 30 days following the positive earnings announcement.
  • The company is executing a buyback program that has contributed to strong share price momentum.
  • Regeneron maintains a resilient cash flow profile and a strong balance sheet, providing stability for future investments.
Risk Factors
  • Analyst consensus fair value of US$869 per share implies the current stock price is approximately 7% overvalued.
  • EYLEA HD faces rising competition in the retinal market which could impact future revenue growth.
  • Ongoing legal issues surrounding Libtayo pose a risk to the franchise's future earnings power.
Full Analysis
Regeneron Pharmaceuticals (REGN) reported strong third-quarter 2026 results, posting revenue of US$5.12 billion and net income of US$1.95 billion. The company delivered a significant earnings beat driven by record contributions from its key franchises Dupixent, EYLEA HD, and Libtayo. Following the announcement, REGN shares surged 13.42% in one day and have gained 22.46% over the past month, reflecting robust market momentum. Analyst consensus currently values Regeneron at a fair price of US$869 per share, implying the stock is approximately 7% overvalued given its current trading price of US$928.61. However, Simply Wall St's discounted cash flow (DCF) model presents a contrasting view, estimating an intrinsic value of US$2,505.69 based on future cash flows. This divergence highlights a debate between traditional analyst targets and fundamental valuation models regarding the stock's current pricing. The company continues to advance a late-stage pipeline in immunology, oncology, genetic medicines, and obesity, with upcoming readouts and regulatory decisions expected to drive future growth. Key risks identified include potential competition for EYLEA HD in the retinal space and ongoing legal issues surrounding Libtayo that could impact earnings power. Investors are weighing these factors against the strong cash generation and resilient balance sheet demonstrated by recent performance.